Listed

OmniAb, Inc.: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 9, 2023 and accepted by EDGAR at Nov 9, 2023, 17:01 ET.

Share

Management's discussion and analysis

As filed, 28,962 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Condition and Results of Operations

*The following discussion and analysis and the unaudited interim financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in the Annual Report on Form 10-K for the year ended December 31, 2022 (the “*2022 Annual Report”).

Forward-Looking Statements

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, our expected cash runway, our business strategy, the effects of the separation or the distribution, our expectations regarding the application of, and the rate and degree of market acceptance of, our OmniAb® technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate, the potential for and timing of receipt of milestones and royalties under our license agreements with partners, our research and development plans, the potential for our partnered or internal programs to progress in their development, the anticipated timing of the initiation and completion of preclinical studies and clinical trials by our partners or us, the timing and likelihood of regulatory filings and product approvals by our partners or us, the potential for and timing and geographic markets of any commercial product launches by our partners and potential for commercial success, our ability to enter into any new, or maintain existing, strategic partnerships or collaborative relationships, our ability to obtain and maintain intellectual property protection for our platform, products and technologies, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated business development and product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risk factors described in Part II, Item 1A, “Risk Factors” of this Quarterly Report. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Overview

Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. We believe that pairing the large and diverse antibody repertoires generated from our proprietary transgenic animals with our cutting-edge and high-throughput validated screening tools will deliver high-quality therapeutic candidates for a wide range of diseases.

Our OmniAb technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies for our partners’ drug development efforts. We harness the power of Biological Intelligence™, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our proprietary host systems for affinity, specificity, developability and functional performance. Our partners have access to these antibody candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and functional and developability characterization. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions. As of September 30, 2023, we had 76 active partners with 314 active programs using the OmniAb technology platform, including 27 OmniAb-derived antibodies in clinical development by our partners, one under regulatory review, and three approved products of our partners: (i) teclistamab, which received accelerated approval in the U.S. for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and conditional marketing authorization in Europe as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, (ii) zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin’s lymphoma, and (iii) sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) non-small cell lung cancer in combination with chemotherapy, as well as for patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.

At the heart of the OmniAb platform is the Biological Intelligence of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® and OmniClic® are common light-chain rats and chickens, respectively, designed to facilitate the production of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. In May 2023, we announced the launch of OmniDeep™, a suite of in silico tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. OmniDeep is designed to facilitate rapid identification of candidates with the right affinity, specificity and developability profiles intended to make drug development more effective and efficient.

We partner with numerous pharmaceutical and biotechnology companies, varying in size, clinical stage, geography and therapeutic focus. Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with partners to typically include: (i) upfront or annual payments for technology access (license revenue), (ii) payments for the performance of research services (service revenue), (iii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue), and (iv) royalties on net sales of our partners’ products. We succeed when our partners are successful and our agreements are structured to align economic and scientific interests. Our typical royalty rates for antibody discovery contracts are currently in the low- to mid-single digits, and can vary depending on the other economic terms in the agreement. Our future success and the potential to receive these payments are entirely dependent on our partners’ efforts over which we have no control. If our partners determine not to proceed with the future development of a drug candidate, we will not receive any future payments related to that program. Additionally, unless publicly disclosed by our partners, we do not have access to information related to our partners’ clinical trial results, including serious adverse events, or ongoing communications with regulatory agencies regarding our partners’ current clinical programs, which limits our visibility into how such programs may be progressing.

Historically, our revenue has been derived from payments for technology access, collaborative research services and milestones. We believe the long-term value of our business will be driven by partner royalties as such payments are based on global sales of potential future partner antibodies, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. We believe our revenue will be materially driven by milestones in the shorter term, and by royalties in the longer term, from our partnered programs in the United States and Europe. However, drug discovery and development has significant uncertainty in timing and likelihood of reaching marketing authorization, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue. Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of antibodies discovered using our platform, and as a result, we are entirely dependent on our partners’ efforts and decisions with respect to such antibodies.

Closing of the Business Combination and Separation from Ligand

On November 1, 2022 (the “Closing Date”), we, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand” or the “Parent”), OmniAb Operations, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (“Legacy OmniAb”, formerly known as OmniAb, Inc. and, together with Ligand, collectively, the “Companies”), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of APAC (“Merger Sub”), consummated the transactions contemplated by the Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 23, 2022.

In connection with, and as contemplated by, the Merger Agreement, on November 1, 2022, in accordance with the terms of the Separation and Distribution Agreement, dated as of March 23, 2022, by and among APAC, Ligand and Legacy OmniAb (the “Separation Agreement”), Ligand transferred the Legacy OmniAb business, including certain related subsidiaries of Ligand, to Legacy OmniAb and made a contribution to the capital of Legacy OmniAb of $1.8 million, after deducting certain transaction and other expenses reimbursable by Legacy OmniAb (the “Separation”). Following the Separation, as contemplated by the Separation Agreement, Ligand distributed on a pro rata basis to its stockholders all of the shares of common stock, par value $0.001 per share, of Legacy OmniAb (“Legacy OmniAb Common Stock”) held by Ligand, such that each holder of shares of common stock, par value $0.001 per share, of Ligand (“Ligand Common Stock”) was entitled to receive one share of

Legacy OmniAb Common Stock for each share of Ligand Common Stock held by such holder as of the record date for the distribution, October 26, 2022 (the “Distribution”).

Following the Separation and Distribution, on November 1, 2022, we consummated the Business Combination, by and among us (formerly known as APAC), Ligand, Legacy OmniAb and Merger Sub, pursuant to which Merger Sub merged with and into Legacy OmniAb, with Legacy OmniAb becoming a wholly owned subsidiary of OmniAb.

Prior to completion of the Separation, on November 1, 2022, Legacy OmniAb operated as part of Ligand and not as a separate, publicly-traded company. Legacy OmniAb’s combined financial statements were derived from Ligand’s historical accounting records and were presented on a carve-out basis. All revenues and expenses as well as assets and liabilities directly associated with Legacy OmniAb’s business activity were included as a component of the combined financial statements. The combined financial statements also included allocations of certain general, administrative, sales and marketing expenses from Ligand’s corporate office and from other Ligand businesses to Legacy OmniAb and allocations of related assets, liabilities, and Ligand’s investment, as applicable. We believe the allocations have been determined on a reasonable basis; however, the amounts were not necessarily representative of the amounts that would have been reflected in the combined financial statements had Legacy OmniAb been an entity that operated separately from Ligand during the periods presented.

Following the Separation, we began accounting for our financial activities as an independent entity. Our financial statements as of December 31, 2022 and September 30, 2023 and for the three and nine months ended September 30, 2023 are based on the reported results of OmniAb as a standalone company. The accompanying condensed consolidated and combined financial statements include the accounts of OmniAb and its wholly owned subsidiaries. All intercompany transactions and accounts within OmniAb have been eliminated.

Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understanding our current business. These metrics may change or may be substituted for additional or different metrics as our business continues to grow.

Metric September 30, 2023 December 31, 2022 % Change
Active partners 76 69 10%
Active programs 314 291 8%
Active clinical programs 31 26 19%
Approved products 3 3 —%

Active partners represents the number of partners that have an active program or have executed a license agreement in advance of initiating an active program. We view this metric as an indication of the competitiveness of our platform and our current level of market penetration. The metric also relates to our opportunities to secure additional active programs.

Active programs represents a program for which research work has commenced or where an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. This number includes active clinical programs and approved products separately disclosed above. We view this metric as an indication of the usage of our technology and the potential for mid- and long-term milestone and royalty payments.

Active clinical programs represents the number of unique programs for which an Investigational New Drug Application or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development by our partners and we continue to count programs as active as long as they are actively being developed, under regulatory review or commercialized. Where the date of such application is not known to us, we use the official start date from clinical trial registries for the purpose of calculating this metric. This number includes approved products separately disclosed below. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

Approved products represents an OmniAb-derived antibody for which our partner has received marketing approval. We view this metric as an indication of our near- and mid-term potential revenue from royalty payments.

Results of Operations

Comparison of the Three And Nine Months Ended September 30, 2023 and 2022

Revenue

(dollars in thousands)

Three Months Ended September 30, 2023 2022 Change % Change
License and milestone revenue $2,010 $1,400 $610 44%
Service revenue 3,016 4,928 (1,912) (39)%
Royalty revenue 451 582 (131) (23)%
Total revenues $5,477 $6,910 $(1,433) (21)%
  • License and milestone revenue fluctuates primarily due to the timing of recognition of milestones related to our partners’ programs in clinical development.
  • Service revenue declined as a result of the completion of work on certain ion channel programs.

(dollars in thousands)

Nine Months Ended September 30, 2023 2022 Change % Change
License and milestone revenue $18,986 $7,826 $11,160 143%
Service revenue 9,425 14,922 (5,497) (37)%
Royalty revenue 931 984 (53) (5)%
Total revenues $29,342 $23,732 $5,610 24%
  • License and milestone revenue increased primarily due to the recognition of a $10.0 million milestone related to the first commercial sale of teclistamab in the E.U. and milestones related to the start of pivotal studies in two additional indications for batoclimab, partially offset by decreases in license and milestone revenue from other programs.
  • Service revenue declined as a result of the completion of work on certain ion channel programs and a one-time adjustment related to the extension of one of our programs with GSK, partially offset by the recognition of a portion of a research progression milestone.

Operating Costs and Expenses

(dollars in thousands)

Three Months Ended September 30, 2023 2022 Change % Change
Research and development $13,867 $13,189 $678 5%
General and administrative 8,511 5,582 2,929 52%
Amortization of intangibles 3,398 3,256 142 4%
Other operating expense (income), net 16 (208) 224 (108)%
Total operating expenses $25,792 $21,819 $3,973 18%
  • Research and development expenses increased primarily due to increased personnel costs.
  • General and administrative expenses increased primarily due to personnel-related costs and costs associated with our obligations as a public company.

(dollars in thousands)

Nine Months Ended September 30, 2023 2022 Change % Change
Research and development $41,759 $35,445 $6,314 18%
General and administrative 25,444 14,697 10,747 73%
Amortization of intangibles 10,147 9,774 373 4%
Other operating expense (income), net 205 (486) 691 (142)%
Total operating expenses $77,555 $59,430 $18,125 30%
  • Research and development expenses increased primarily due to increased personnel costs and rent expense for newly leased facilities as we invested in the growth and development of our business.
  • General and administrative expenses increased primarily due to personnel-related costs and costs associated with our obligations as a public company.
  • The change in other operating expense (income), net was primarily due to fair value adjustments to contingent earnout liabilities and increases in royalty expense associated with higher revenue.

Other Income

Other income during the three and nine months ended September 30, 2023 related to interest earned on short-term investments. There was no other income during the three and nine months ended September 30, 2022.

Income Tax Benefit

(dollars in thousands)

Three Months Ended September 30, 2023 2022 Change % Change
Loss before income tax benefit $(19,042) $(14,909) $(4,133) 28%
Income tax benefit 3,304 2,313 991 43%
Net loss $(15,738) $(12,596) $(3,142) 25%
Effective Tax Rate (17.4)% (15.5)%

(dollars in thousands)

Nine Months Ended September 30, 2023 2022 Change % Change
Loss before income tax benefit $(44,335) $(35,698) $(8,637) 24%
Income tax benefit 7,769 6,544 1,225 19%
Net loss $(36,566) $(29,154) $(7,412) 25%
Effective Tax Rate (17.5)% (18.3)%

Our effective tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions. The tax rate is also affected by discrete items that may occur in any given year but are not consistent from year to year.

Our effective tax rate for the three and nine months ended September 30, 2023 differed from the federal statutory tax rate of 21.0% due to share-based compensation expense that is not tax deductible and an increase to our valuation allowance recorded against deferred tax assets, partially offset by the tax benefit from research and development tax credits. Our effective tax rate for the three and nine months ended September 30, 2022 differed from the federal statutory tax rate of 21.0% due to share-based compensation expense that is not tax deductible, an increase to our valuation allowance recorded against deferred tax assets, and repricing of state tax deferrals, partially offset by the tax benefit of research and development tax credits.

Liquidity and Capital Resources

Prior to November 1, 2022, funding from Ligand was our primary source of liquidity. On November 1, 2022, with the closing of the Business Combination, we were capitalized with $95.8 million in net cash. As of September 30, 2023, our cash, cash equivalents and short-term investments were $96.6 million. We believe our cash, cash equivalents and short-term investments and the cash we expect to generate from operations will provide us the flexibility we need to meet operating, investing, and financing needs and support our operations through at least the next 12 months.

If our anticipated cash flows from operations and current cash are insufficient to satisfy our liquidity requirements because of increased expenditures or lower demand for our technology platform, or the realization of other risks, we may be required to raise additional capital through issuances of public or private equity or debt financing or other capital sources. Such additional financing may not be available on terms acceptable to us or at all. In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments or acquisitions, to take advantage of favorable market conditions or financing opportunities or for other reasons. Our future capital requirements will depend on many factors, including, but not limited to:

  • our ability to achieve revenue growth;
  • the costs of expanding our operations, including our business development and marketing efforts;
  • our rate of progress in selling access to our platform and marketing activities associated therewith;
  • our rate of progress in, and cost of research and development activities associated with, our platform technologies and our internal developed programs to the extent we pursue any such programs;
  • the effect of competing technological and market developments;
  • the impact of pandemics or epidemic diseases on global social, political and economic conditions;
  • our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company;
  • the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property and proprietary rights; and
  • the costs associated with any technologies that we may in-license or acquire.

We anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.

Additionally, we may receive up to $218.6 million from the exercise of the Warrants, assuming the exercise in full of all the Warrants for cash, but not from the sale of the shares of our common stock issuable upon such exercise. As of the date of this report, our Warrants are “out of the money,” which means that the trading price of the shares of our common stock underlying our Warrants is below the $11.50 exercise price of the Warrants. For so long as the Warrants remain out of the money, we do not expect warrant holders to exercise their Warrants. Therefore, any cash proceeds that we may receive in relation to the exercise of such securities will be dependent on the trading price of our common stock. If the market price for our common stock is less than the exercise price of the Warrants, warrant holders will be unlikely to exercise such securities. We expect to use the net proceeds from the exercise of the Warrants, if any, for general corporate and working capital purposes, although we believe we can fund our operations with cash on hand.

Cash Flow Summary

(dollars in thousands)

Net cash provided by (used in): Nine Months Ended September 30, 2023 2022 Change
Operating activities $11,468 $3,556 $7,912
Investing activities (23,106) (13,112) (9,994)
Financing activities $(396) $9,556 $(9,952)

Cash from Operating Activities:

During the nine months ended September 30, 2023, cash provided by operating activities of $11.5 million primarily reflected changes in our operating assets and liabilities in the amount of $24.9 million, net non-cash charges of $23.2 million which primarily included $18.9 million in share-based compensation, and $14.6 million in depreciation and amortization, partially offset by our net loss of $36.6 million, $7.5 million of deferred income taxes, net and $2.7 million of amortization of discounts on short-term investments, net.

During the nine months ended September 30, 2022, cash provided by operating activities of $3.6 million primarily reflected changes in our operating assets and liabilities in the amount of $14.5 million, net non-cash charges of $18.2 million which primarily included $12.3 million in share-based compensation, and $13.4 million in depreciation and amortization, partially offset by our net loss of $29.2 million and $6.8 million of deferred income taxes, net.

Cash from Investing Activities:

During the nine months ended September 30, 2023, cash used in investing activities of $23.1 million primarily consisted of $86.9 million of cash used to purchase short-term investments and $3.6 million of payments to contingent liabilities holders, partially offset by $66.3 million of proceeds from the maturity of short-term investments and $2.7 million from the sale of short-term investments.

During the nine months ended September 30, 2022, cash used in investing activities of $13.1 million primarily consisted of $12.2 million of property and equipment purchases and $1.0 million of payments to contingent liabilities holders.

Cash from Financing Activities:

As Ligand managed our cash and financing arrangements prior to the completion of the Separation, all excess cash generated through earnings was deemed remitted to Ligand and all sources of cash were deemed funded by Ligand.

During the nine months ended September 30, 2023, cash used by financing activities was $0.4 million which primarily consisted of $0.9 million of taxes paid related to the net share settlement of equity awards and $0.5 million of transaction costs, partially offset by $1.0 million of proceeds from the issuance of common stock from stock plans.

During the nine months ended September 30, 2022, cash provided by financing activities was $9.6 million which primarily consisted of a $15.3 million net transfer from Ligand, partially offset by $4.2 million of transaction costs and $1.5 million of payments to contingent liabilities holders.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2023, as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2022 Annual Report.

Recent Accounting Pronouncements

For the summary of recent accounting pronouncements, see Note 2 – Summary of Significant Accounting Policies to our financial statements included in this Quarterly Report.

Market risk

As filed, 143 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of September 30, 2023, there were no material changes to our market risks from the discussion provided in Item 7A of our 2022 Annual Report.

Controls and procedures

As filed, 2,424 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2023, the end of the period covered by this Quarterly Report. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 501 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2022 Annual Report. The risk factors described in our 2022 Annual Report are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-07-01 to 2023-09-30$5.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2023-01-01 to 2023-09-30$29.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2023-07-01 to 2023-09-30$13.9mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2023-01-01 to 2023-09-30$41.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-07-01 to 2023-09-30−$20.3mus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30−$48.2mus-gaap:OperatingIncomeLoss
Income tax3 months2023-07-01 to 2023-09-30−$3.3mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2023-01-01 to 2023-09-30−$7.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-01 to 2023-09-30−$15.7mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30−$36.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30−$0.16us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30−$0.37us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30−$0.16us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30−$0.37us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-3099,905,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-3099,521,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30$11.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2023-01-01 to 2023-09-30$1.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-09-30$21.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$106.8mus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$391.7mus-gaap:Assets
Current liabilitiesAt period end2023-09-30$25.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$67.2mus-gaap:Liabilities
Shareholders' equityAt period end2023-09-30$324.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001846253-23-000120. Last ingested by Listed: Nov 2, 2026, 16:29 ET. Listed shows no prices and gives no investment advice.